{"name":"Biogen Inc.","slug":"biogen","ticker":"BIIB","exchange":"NASDAQ","domain":"biogen.com","description":"Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.","hq":"Cambridge, MA","founded":0,"employees":"7500","ceo":"Christopher Viehbacher","sector":"Biotech","stockPrice":177.09,"stockChange":1.48,"stockChangePercent":0.84,"marketCap":"$26.0B","metrics":{"revenue":9890600000,"revenueGrowth":-7.1,"grossMargin":78.9,"rdSpend":1334919000,"netIncome":1292900000,"cash":2913700000,"dividendYield":0,"peRatio":20.1,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Tecfidera","genericName":"DIMETHYL FUMARATE","slug":"dimethyl-fumarate","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":37.3},{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":21.3},{"name":"Avonex","genericName":"INTERFERON BETA-1A","slug":"interferon-beta-1a","revenue":800000000,"yoyGrowth":0,"percentOfTotal":10.7},{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","revenue":800000000,"yoyGrowth":0,"percentOfTotal":10.7},{"name":"Vumerity","genericName":"DIROXIMEL FUMARATE","slug":"diroximel-fumarate","revenue":500000000,"yoyGrowth":0,"percentOfTotal":6.7},{"name":"fampridine","genericName":"fampridine","slug":"fampridine","revenue":400000000,"yoyGrowth":0,"percentOfTotal":5.3},{"name":"Skyclarys","genericName":"OMAVELOXOLONE","slug":"omaveloxolone","revenue":300000000,"yoyGrowth":0,"percentOfTotal":4},{"name":"Qalsody","genericName":"TOFERSEN","slug":"tofersen","revenue":200000000,"yoyGrowth":0,"percentOfTotal":2.7},{"name":"Zurzuvae","genericName":"ZURANOLONE","slug":"zuranolone","revenue":100000000,"yoyGrowth":0,"percentOfTotal":1.3}],"timeline":[{"date":"1996-01-01","label":"Avonex first approved","drug":"Avonex","drugSlug":"interferon-beta-1a","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Tysabri first approved","drug":"Tysabri","drugSlug":"natalizumab","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Tecfidera first approved","drug":"Tecfidera","drugSlug":"dimethyl-fumarate","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Plegridy first approved","drug":"Plegridy","drugSlug":"peginterferon-beta-1a","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Vumerity first approved","drug":"Vumerity","drugSlug":"diroximel-fumarate","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Aduhelm first approved","drug":"Aduhelm","drugSlug":"aducanumab","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Skyclarys first approved","drug":"Skyclarys","drugSlug":"omaveloxolone","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Qalsody first approved","drug":"Qalsody","drugSlug":"tofersen","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Zurzuvae first approved","drug":"Zurzuvae","drugSlug":"zuranolone","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Tysabri patent cliff ($2.5B at risk)","drug":"Tysabri","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Aduhelm patent cliff ($1.5B at risk)","drug":"Aduhelm","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":4400000000,"percentOfTotal":58.7,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Tecfidera","genericName":"DIMETHYL FUMARATE","slug":"dimethyl-fumarate","indication":"Plaque psoriasis","status":"marketed","revenue":2800000000},{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","indication":"Multiple Sclerosis","status":"marketed","revenue":1600000000},{"name":"ASA","genericName":"ASA","slug":"asa","indication":"Cardiovascular disease prevention (secondary prevention post-myocardial infarction, stroke, or transient ischemic attack)","status":"marketed"},{"name":"BG00002 (natalizumab)","genericName":"BG00002 (natalizumab)","slug":"bg00002-natalizumab","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"},{"name":"BIIB059 (litifilimab)","genericName":"BIIB059 (litifilimab)","slug":"biib059-litifilimab","indication":"Systemic lupus erythematosus (SLE)","status":"phase_3"},{"name":"Baminercept alfa 4","genericName":"Baminercept alfa 4","slug":"baminercept-alfa-4","indication":"Moderate to severe plaque psoriasis","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":2600000000,"percentOfTotal":34.7,"drugCount":26,"colorKey":"immunology","drugs":[{"name":"Avonex","genericName":"INTERFERON BETA-1A","slug":"interferon-beta-1a","indication":"Relapsing remitting multiple sclerosis","status":"marketed","revenue":800000000},{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","indication":"Relapsing remitting multiple sclerosis","status":"marketed","revenue":800000000},{"name":"Vumerity","genericName":"DIROXIMEL FUMARATE","slug":"diroximel-fumarate","indication":"Relapsing Forms of Multiple Sclerosis","status":"marketed","revenue":500000000},{"name":"fampridine","genericName":"fampridine","slug":"fampridine","indication":"Multiple sclerosis","status":"marketed","revenue":400000000},{"name":"Zurzuvae","genericName":"ZURANOLONE","slug":"zuranolone","indication":"Postpartum Depression","status":"marketed","revenue":100000000},{"name":"Standard of Care IST","genericName":"Standard of Care IST","slug":"standard-of-care-ist","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"Spinraza","genericName":"NUSINERSEN","slug":"nusinersen","indication":"Spinal muscular atrophy","status":"marketed"},{"name":"ADUHELM","genericName":"ADUCANUMAB-AVWA","slug":"aducanumab-avwa","indication":"Alzheimer's disease","status":"marketed"},{"name":"ALKS 8700","genericName":"ALKS 8700","slug":"alks-8700","indication":"Schizophrenia","status":"phase_3"},{"name":"Aduhelm","genericName":"ADUCANUMAB","slug":"aducanumab","indication":"Alzheimer's disease","status":"marketed"},{"name":"Avonex","genericName":"Avonex","slug":"avonex","indication":"Relapsing remitting multiple sclerosis","status":"marketed"},{"name":"BG00010","genericName":"BG00010","slug":"bg00010","indication":"Alzheimer's disease","status":"phase_2"},{"name":"BG00012 (DMF)","genericName":"BG00012 (DMF)","slug":"bg00012-dmf","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"marketed"},{"name":"BG00012 (dimethyl fumarate)","genericName":"BG00012 (dimethyl fumarate)","slug":"bg00012-dimethyl-fumarate","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"},{"name":"BG9418 (interferon beta-1a)","genericName":"BG9418 (interferon beta-1a)","slug":"bg9418-interferon-beta-1a","indication":"Multiple sclerosis (relapsing-remitting or relapsing forms)","status":"phase_3"},{"name":"BIIB041 (Fampridine-SR)","genericName":"BIIB041 (Fampridine-SR)","slug":"biib041-fampridine-sr","indication":"Multiple sclerosis (MS) — to improve walking speed and motor function","status":"phase_3"},{"name":"BIIB041 (fampridine)","genericName":"BIIB041 (fampridine)","slug":"biib041-fampridine","indication":"Multiple sclerosis with gait impairment","status":"phase_3"},{"name":"BIIB104","genericName":"BIIB104","slug":"biib104","indication":"LRRK2-associated Parkinson's disease","status":"phase_2"},{"name":"BIIB122","genericName":"BIIB122","slug":"biib122","indication":"Multiple sclerosis (remyelination)","status":"phase_3"},{"name":"Interferon beta type 1a","genericName":"Interferon beta type 1a","slug":"interferon-beta-type-1a","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"Interferon beta-1a (Avonex)","genericName":"Interferon beta-1a (Avonex)","slug":"interferon-beta-1a-avonex","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"},{"name":"Placebo matching DMF","genericName":"Placebo matching DMF","slug":"placebo-matching-dmf","indication":"Relapsing-remitting multiple sclerosis (as control in Phase 3 trials)","status":"phase_3"},{"name":"Placebo matching fingolimod","genericName":"Placebo matching fingolimod","slug":"placebo-matching-fingolimod","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"TYSABRI and AVONEX","genericName":"TYSABRI and AVONEX","slug":"tysabri-and-avonex","indication":"Relapsing-remitting multiple sclerosis (TYSABRI)","status":"marketed"},{"name":"injectable MS DMT","genericName":"injectable MS DMT","slug":"injectable-ms-dmt","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"},{"name":"low immunogenic interferon-beta-1a","genericName":"low immunogenic interferon-beta-1a","slug":"low-immunogenic-interferon-beta-1a","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":500000000,"percentOfTotal":6.7,"drugCount":25,"colorKey":"cardiovascular","drugs":[{"name":"Skyclarys","genericName":"OMAVELOXOLONE","slug":"omaveloxolone","indication":"Friedreich’s ataxia","status":"marketed","revenue":300000000},{"name":"Qalsody","genericName":"TOFERSEN","slug":"tofersen","indication":"Amyotrophic lateral sclerosis","status":"marketed","revenue":200000000},{"name":"BIIB033","genericName":"BIIB033","slug":"biib033","indication":"Other","status":"phase_2"},{"name":"BIIB111","genericName":"BIIB111","slug":"biib111","indication":"Other","status":"phase_2"},{"name":"11^C]BIO-1819578","genericName":"11^C]BIO-1819578","slug":"11-c-bio-1819578","indication":"Other","status":"phase_1"},{"name":"14C-BIIB061","genericName":"14C-BIIB061","slug":"14c-biib061","indication":"Other","status":"phase_1"},{"name":"99mTc-MAG3-BIIB067","genericName":"99mTc-MAG3-BIIB067","slug":"99mtc-mag3-biib067","indication":"Other","status":"phase_1"},{"name":"BG00002","genericName":"BG00002","slug":"bg00002","indication":"Other","status":"marketed"},{"name":"BG00010 SC","genericName":"BG00010 SC","slug":"bg00010-sc","indication":"Other","status":"phase_1"},{"name":"BIIB076","genericName":"BIIB076","slug":"biib076","indication":"Other","status":"phase_1"},{"name":"BIIB080","genericName":"BIIB080","slug":"biib080","indication":"Other","status":"phase_2"},{"name":"Baminercept alfa 1","genericName":"Baminercept alfa 1","slug":"baminercept-alfa-1","indication":"Other","status":"phase_2"},{"name":"Baminercept alfa 2","genericName":"Baminercept alfa 2","slug":"baminercept-alfa-2","indication":"Other","status":"phase_2"},{"name":"Baminercept alfa 5","genericName":"Baminercept alfa 5","slug":"baminercept-alfa-5","indication":"Other","status":"phase_2"},{"name":"CNV1014802","genericName":"CNV1014802","slug":"cnv1014802","indication":"Other","status":"phase_2"},{"name":"Control medium","genericName":"Control medium","slug":"control-medium","indication":"Other","status":"marketed"},{"name":"GSK drug","genericName":"GSK drug","slug":"gsk-drug","indication":"Other","status":"phase_1"},{"name":"Omaveloxolone Capsules, 150 mg","genericName":"Omaveloxolone Capsules, 150 mg","slug":"omaveloxolone-capsules-150-mg","indication":"Other","status":"phase_2"},{"name":"Placebo matching DRF","genericName":"Placebo matching DRF","slug":"placebo-matching-drf","indication":"Other","status":"phase_3"},{"name":"TOFIDENCE","genericName":"TOCILIZUMAB-BAVI","slug":"tocilizumab-bavi","indication":"Other","status":"marketed"},{"name":"Verapamil Pill","genericName":"Verapamil Pill","slug":"verapamil-pill","indication":"Other","status":"phase_1"},{"name":"[14C]-BIIB091","genericName":"[14C]-BIIB091","slug":"14c-biib091","indication":"Other","status":"phase_1"},{"name":"[89Zr]Zr-DFO-BIIB080","genericName":"[89Zr]Zr-DFO-BIIB080","slug":"89zr-zr-dfo-biib080","indication":"Other","status":"phase_1"},{"name":"dimethyl fumarate - Reference form","genericName":"dimethyl fumarate - Reference form","slug":"dimethyl-fumarate-reference-form","indication":"Other","status":"phase_1"},{"name":"tetanus diphtheria toxoids vaccine","genericName":"tetanus diphtheria toxoids vaccine","slug":"tetanus-diphtheria-toxoids-vaccine","indication":"Prevention of tetanus","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"exemestane (Aromasin)","genericName":"exemestane (Aromasin)","slug":"exemestane-aromasin","indication":"Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings)","status":"phase_3"},{"name":"BIIB014","genericName":"BIIB014","slug":"biib014","indication":"Relapsed or refractory non-Hodgkin's lymphoma","status":"phase_2"},{"name":"BIIB091","genericName":"BIIB091","slug":"biib091","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Baminercept alfa 3","genericName":"Baminercept alfa 3","slug":"baminercept-alfa-3","indication":"Idiopathic pulmonary fibrosis","status":"phase_2"}]}],"pipeline":[{"name":"Tecfidera","genericName":"DIMETHYL FUMARATE","slug":"dimethyl-fumarate","phase":"marketed","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system.","indications":["Plaque psoriasis","Relapsing remitting multiple sclerosis"],"catalyst":""},{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","phase":"marketed","mechanism":"Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease.","indications":["Multiple Sclerosis","Crohn's Disease"],"catalyst":""},{"name":"Avonex","genericName":"INTERFERON BETA-1A","slug":"interferon-beta-1a","phase":"marketed","mechanism":"Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.","indications":["Relapsing remitting multiple sclerosis"],"catalyst":""},{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","phase":"marketed","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.","indications":["Relapsing remitting multiple sclerosis"],"catalyst":""},{"name":"Vumerity","genericName":"DIROXIMEL FUMARATE","slug":"diroximel-fumarate","phase":"marketed","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system.","indications":["Relapsing Forms of Multiple Sclerosis"],"catalyst":""},{"name":"fampridine","genericName":"fampridine","slug":"fampridine","phase":"marketed","mechanism":"Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2","indications":["Multiple sclerosis"],"catalyst":""},{"name":"Skyclarys","genericName":"OMAVELOXOLONE","slug":"omaveloxolone","phase":"marketed","mechanism":"Skyclarys works by activating the Nrf2 pathway to increase the production of antioxidant proteins that protect cells from damage.","indications":["Friedreich’s ataxia"],"catalyst":""},{"name":"Qalsody","genericName":"TOFERSEN","slug":"tofersen","phase":"marketed","mechanism":"Qalsody works by binding to the messenger RNA (mRNA) of the Superoxide dismutase 1 (SOD1) gene, preventing its expression and reducing the production of the toxic SOD1 protein associated with ALS.","indications":["Amyotrophic lateral sclerosis"],"catalyst":""},{"name":"Zurzuvae","genericName":"ZURANOLONE","slug":"zuranolone","phase":"marketed","mechanism":"Zurzuvae works by binding to the GABA A receptor, enhancing the inhibitory effects of GABA to calm overactive neurons.","indications":["Postpartum Depression"],"catalyst":""},{"name":"Standard of Care IST","genericName":"Standard of Care IST","slug":"standard-of-care-ist","phase":"phase_3","mechanism":"IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.","indications":["Relapsing forms of multiple sclerosis","Active secondary progressive multiple sclerosis"],"catalyst":""},{"name":"ASA","genericName":"ASA","slug":"asa","phase":"marketed","mechanism":"ASA (acetylsalicylic acid) irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","indications":["Cardiovascular disease prevention (secondary prevention post-myocardial infarction, stroke, or transient ischemic attack)","Acute coronary syndrome","Pain and fever","Rheumatoid arthritis and other inflammatory conditions"],"catalyst":""},{"name":"BIIB033","genericName":"BIIB033","slug":"biib033","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB111","genericName":"BIIB111","slug":"biib111","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Spinraza","genericName":"NUSINERSEN","slug":"nusinersen","phase":"marketed","mechanism":"Spinraza works by binding to a specific genetic sequence to increase production of a protein that helps maintain muscle function.","indications":["Spinal muscular atrophy"],"catalyst":""},{"name":"exemestane (Aromasin)","genericName":"exemestane (Aromasin)","slug":"exemestane-aromasin","phase":"phase_3","mechanism":"Exemestane is a steroidal aromatase inhibitor that blocks the enzyme aromatase, reducing estrogen production in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings)","Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"11^C]BIO-1819578","genericName":"11^C]BIO-1819578","slug":"11-c-bio-1819578","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-BIIB061","genericName":"14C-BIIB061","slug":"14c-biib061","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"99mTc-MAG3-BIIB067","genericName":"99mTc-MAG3-BIIB067","slug":"99mtc-mag3-biib067","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADUHELM","genericName":"ADUCANUMAB-AVWA","slug":"aducanumab-avwa","phase":"marketed","mechanism":"Amyloid beta A4 protein","indications":["Alzheimer's disease"],"catalyst":""},{"name":"ALKS 8700","genericName":"ALKS 8700","slug":"alks-8700","phase":"phase_3","mechanism":"ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation.","indications":["Schizophrenia","Bipolar I disorder"],"catalyst":""},{"name":"Aduhelm","genericName":"ADUCANUMAB","slug":"aducanumab","phase":"marketed","mechanism":"Amyloid beta A4 protein","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Avonex","genericName":"Avonex","slug":"avonex","phase":"marketed","mechanism":"Interferon alpha/beta receptor","indications":["Relapsing remitting multiple sclerosis"],"catalyst":""},{"name":"BG00002","genericName":"BG00002","slug":"bg00002","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BG00002 (natalizumab)","genericName":"BG00002 (natalizumab)","slug":"bg00002-natalizumab","phase":"marketed","mechanism":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Crohn's disease"],"catalyst":""},{"name":"BG00010","genericName":"BG00010","slug":"bg00010","phase":"phase_2","mechanism":"BG00010 is a monoclonal antibody targeting amyloid beta.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"BG00010 SC","genericName":"BG00010 SC","slug":"bg00010-sc","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BG00012 (DMF)","genericName":"BG00012 (DMF)","slug":"bg00012-dmf","phase":"marketed","mechanism":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and neuroinflammation.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Primary progressive multiple sclerosis (PPMS)"],"catalyst":""},{"name":"BG00012 (dimethyl fumarate)","genericName":"BG00012 (dimethyl fumarate)","slug":"bg00012-dimethyl-fumarate","phase":"phase_3","mechanism":"Dimethyl fumarate activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which reduces oxidative stress and inflammatory responses in immune cells.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"BG9418 (interferon beta-1a)","genericName":"BG9418 (interferon beta-1a)","slug":"bg9418-interferon-beta-1a","phase":"phase_3","mechanism":"BG9418 is interferon beta-1a, which activates interferon signaling pathways to modulate immune responses and reduce inflammation.","indications":["Multiple sclerosis (relapsing-remitting or relapsing forms)"],"catalyst":""},{"name":"BIIB014","genericName":"BIIB014","slug":"biib014","phase":"phase_2","mechanism":"BIIB014 is a monoclonal antibody targeting CD20.","indications":["Relapsed or refractory non-Hodgkin's lymphoma"],"catalyst":""},{"name":"BIIB041 (Fampridine-SR)","genericName":"BIIB041 (Fampridine-SR)","slug":"biib041-fampridine-sr","phase":"phase_3","mechanism":"Fampridine-SR is a potassium channel blocker that enhances nerve impulse conduction by blocking potassium efflux, thereby improving motor function in patients with multiple sclerosis.","indications":["Multiple sclerosis (MS) — to improve walking speed and motor function"],"catalyst":""},{"name":"BIIB041 (fampridine)","genericName":"BIIB041 (fampridine)","slug":"biib041-fampridine","phase":"phase_3","mechanism":"Fampridine is a potassium channel blocker that enhances nerve impulse conduction by blocking potassium efflux, thereby improving motor function in demyelinating diseases.","indications":["Multiple sclerosis with gait impairment","Spinal cord injury (Phase 3 development)"],"catalyst":""},{"name":"BIIB059 (litifilimab)","genericName":"BIIB059 (litifilimab)","slug":"biib059-litifilimab","phase":"phase_3","mechanism":"Litifilimab is a monoclonal antibody that blocks B7-related protein 1 (BR1), an immune checkpoint molecule that suppresses T cell activation.","indications":["Systemic lupus erythematosus (SLE)"],"catalyst":""},{"name":"BIIB076","genericName":"BIIB076","slug":"biib076","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB080","genericName":"BIIB080","slug":"biib080","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB091","genericName":"BIIB091","slug":"biib091","phase":"phase_2","mechanism":"BIIB091 is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BIIB104","genericName":"BIIB104","slug":"biib104","phase":"phase_2","mechanism":"BIIB104 is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neuronal cells.","indications":["LRRK2-associated Parkinson's disease"],"catalyst":""},{"name":"BIIB122","genericName":"BIIB122","slug":"biib122","phase":"phase_3","mechanism":"BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system.","indications":["Multiple sclerosis (remyelination)"],"catalyst":""},{"name":"Baminercept alfa 1","genericName":"Baminercept alfa 1","slug":"baminercept-alfa-1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Baminercept alfa 2","genericName":"Baminercept alfa 2","slug":"baminercept-alfa-2","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Baminercept alfa 3","genericName":"Baminercept alfa 3","slug":"baminercept-alfa-3","phase":"phase_2","mechanism":"Baminercept alfa 3 is a fusion protein that targets and modulates the activity of TGF-beta superfamily members.","indications":["Idiopathic pulmonary fibrosis"],"catalyst":""},{"name":"Baminercept alfa 4","genericName":"Baminercept alfa 4","slug":"baminercept-alfa-4","phase":"phase_2","mechanism":"Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Baminercept alfa 5","genericName":"Baminercept alfa 5","slug":"baminercept-alfa-5","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CNV1014802","genericName":"CNV1014802","slug":"cnv1014802","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Control medium","genericName":"Control medium","slug":"control-medium","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GSK drug","genericName":"GSK drug","slug":"gsk-drug","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Interferon beta type 1a","genericName":"Interferon beta type 1a","slug":"interferon-beta-type-1a","phase":"phase_3","mechanism":"Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Clinically isolated syndrome with MRI features consistent with multiple sclerosis"],"catalyst":""},{"name":"Interferon beta-1a (Avonex)","genericName":"Interferon beta-1a (Avonex)","slug":"interferon-beta-1a-avonex","phase":"marketed","mechanism":"Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity in the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis with active disease"],"catalyst":""},{"name":"Omaveloxolone Capsules, 150 mg","genericName":"Omaveloxolone Capsules, 150 mg","slug":"omaveloxolone-capsules-150-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo matching DMF","genericName":"Placebo matching DMF","slug":"placebo-matching-dmf","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration characteristics of dimethyl fumarate (DMF) for blinded clinical trial purposes.","indications":["Relapsing-remitting multiple sclerosis (as control in Phase 3 trials)"],"catalyst":""},{"name":"Placebo matching DRF","genericName":"Placebo matching DRF","slug":"placebo-matching-drf","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration characteristics of an active investigational drug in a blinded clinical trial.","indications":[],"catalyst":""},{"name":"Placebo matching fingolimod","genericName":"Placebo matching fingolimod","slug":"placebo-matching-fingolimod","phase":"phase_3","mechanism":"Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis"],"catalyst":""},{"name":"TOFIDENCE","genericName":"TOCILIZUMAB-BAVI","slug":"tocilizumab-bavi","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"TYSABRI and AVONEX","genericName":"TYSABRI and AVONEX","slug":"tysabri-and-avonex","phase":"marketed","mechanism":"TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis.","indications":["Relapsing-remitting multiple sclerosis (TYSABRI)","Clinically isolated syndrome suggestive of multiple sclerosis (AVONEX)","Relapsing multiple sclerosis (AVONEX)"],"catalyst":""},{"name":"Verapamil Pill","genericName":"Verapamil Pill","slug":"verapamil-pill","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-BIIB091","genericName":"[14C]-BIIB091","slug":"14c-biib091","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[89Zr]Zr-DFO-BIIB080","genericName":"[89Zr]Zr-DFO-BIIB080","slug":"89zr-zr-dfo-biib080","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"dimethyl fumarate - Reference form","genericName":"dimethyl fumarate - Reference form","slug":"dimethyl-fumarate-reference-form","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"injectable MS DMT","genericName":"injectable MS DMT","slug":"injectable-ms-dmt","phase":"marketed","mechanism":"Injectable MS DMT refers to disease-modifying therapies for multiple sclerosis administered by injection that work through various immunomodulatory mechanisms to reduce inflammation and slow disease progression.","indications":["Relapsing-remitting multiple sclerosis","Clinically isolated syndrome with MRI features consistent with MS"],"catalyst":""},{"name":"low immunogenic interferon-beta-1a","genericName":"low immunogenic interferon-beta-1a","slug":"low-immunogenic-interferon-beta-1a","phase":"marketed","mechanism":"Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis"],"catalyst":""},{"name":"tetanus diphtheria toxoids vaccine","genericName":"tetanus diphtheria toxoids vaccine","slug":"tetanus-diphtheria-toxoids-vaccine","phase":"marketed","mechanism":"The tetanus diphtheria toxoids vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity against these bacterial diseases.","indications":["Prevention of tetanus","Prevention of diphtheria"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Biogen Reports Fourth-Quarter and Full-Year 2022 Financial Results","summary":"Biogen reported fourth-quarter and full-year 2022 financial results, with revenue of $5.6 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-03-18","type":"deal","headline":"Biogen and Eisai Announce Collaboration to Develop and Commercialize Lecanemab","summary":"Biogen and Eisai announced a collaboration to develop and commercialize lecanemab, a potential treatment for Alzheimer's disease.","drugName":"","sentiment":"positive"},{"date":"2021-06-07","type":"regulatory","headline":"FDA Approves Aduhelm for Alzheimer's Disease","summary":"The FDA approved Aduhelm, a treatment for Alzheimer's disease, marking a significant milestone for Biogen.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNN2JuVXJyZFItOWxCMjBsaGgtYk0zRFE0OERBUmp5dHIwaVJlY0Q0TkJvb2lqazJVbzVNTGJMY2swZDdjeUZQR3lvS2lRc2Z2aEFVTk5uY21GSjh1ajBKX0l4d0ZhNnJCSkUwZS1HSWRaVGhMdmxha3htWWp2eDRIdk1URlByZVdLQW9rNmlxMTZzQVRzTEZGc3Fwa2ZwN2hqaXBobFVUTXdKSlh6VEhuUERBODA1SC1jYzdEdC04V2plMVk?oc=5","date":"2026-04-01","type":"deal","source":"TradingView","summary":"Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - TradingView","headline":"Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPaF9YMjdJcFgzOGxiM2xJblBMd1JDYVZVNHVhSTA2cnpmSzFIS1lfT1BfeEhISm5MbEJ5YmdvN0JFb0JPX0xfOGh4RlhXWnFxb052aTlHXy1VM0o1c0tvdmxHS0U5ZnpOTkctQzI1VzhNZ3JvR2pXZUtjVUIya0NtTU54UHR1cnpHVVlBYi1TM3ZXdlN3SkJqRHBOSk5PMUwtQks3dDRVT0hSNEZ1NEdWV0hBdjFGYWIzdHRlYk53?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Biogen bets $5.6B on kidney and eye drugs in Apellis takeover - Stock Titan","headline":"Biogen bets $5.6B on kidney and eye drugs in Apellis takeover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeTYyQXlmLXRZbEJRVURhb2tITmUzcWxfMUhiSjRCRjkxajItRGgyMDlxdUs3MG1wT3NpdUNhZUxCQzVpSVQzMTZuZjlhN1ZxazBiMHFveXBYbFhMSEJiUGNtb1JfSUpzQ3YzQ1l4SzBHTnp5STVMTFpNd05WSkk3c0xVelhfWmhDWjJ5QUc0QVhpNHpSekVmNnZpM1VkYjdDLVgtZllVVmpoLWFaZkp6U29sY0tyT1FKYVBqR29CTTdsb3BpMG1EVkM2UzlKTC1fM01YbGxYYWljRlZwZWNkN0JOV0xuZm1fRmc?oc=5","date":"2026-03-31","type":"deal","source":"proactiveinvestors.com","summary":"Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio - proactiveinvestors.com","headline":"Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNTE2VUZRWHRNOE8zRUw3U1ItOHp2bkxza3Zjc1RuNmJtUXJQTm5TbC12cTJVR09tNW1yaTluYV8yZjFiZjdsN1ZfN3RnQXFGMERyckllRmxPU2kyZE14bFNSeFVTdXA3eTZqejlUUk03a1hqeTNtaDBDUHVsTzFvaWVETXhSNkI1RzcxeXlPRlZTdjk4U2Q5YWlGcXMtYW8zYkluUll3UTVjUXc?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"Why Is Apellis Stock Skyrocketing Tuesday? - Apellis Pharmaceuticals (NASDAQ:APLS), Biogen (NASDAQ:BIIB) - Benzinga","headline":"Why Is Apellis Stock Skyrocketing Tuesday? - Apellis Pharmaceuticals (NASDAQ:APLS), Biogen (NASDAQ:BIIB)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQemg5TEFsaHhMV0RqOXJjb3JIVDBZU2Jyd2xqOFdxem5vZFdYamNxRGZDcDJzM2gwMFM4ZE5CQkVKN1I4NExEWm8wa3ByY2ctR1RLdXNaczBONXZ3a0RRWVBQTHFWS3hFbVdWWlpGNnR3RHBxZUNjS1oyVWFSNGFhN2dPQ1Zualhja1NIZmNXRzB3NW1yQnFn?oc=5","date":"2026-02-13","type":"pipeline","source":"Finviz","summary":"Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why - Finviz","headline":"Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQdnFRbVl4TTZndXFtQmVjd3Z5N2NEUnZPR2NxTkQ1cElyMTBEWXN4VWlKanNwUk1uXzVTR2VPbkZyWl9ralcyVGN6VzlFV1JxaHJoRk4xSDl1el9hbEMwRlRxOV82Q2g4MHdzOEhpWXlRcm9WbDVMYzdNUzFNZmJzT0RyYUVoVGZfSDliZV9rNGIzWl9xXzZNbE5ja3ExUQ?oc=5","date":"2026-01-29","type":"regulatory","source":"Finviz","summary":"Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status - Finviz","headline":"Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQbmJVZHlWNnNab0pGNmpBZ3lOSnJQUDF5UTRYdElQMW1JQmlqb2IzVlBqbmFpZzZZY2dYeDd4ejdla3dOOFpUWUI0V0VseVNnc2lBdHhjZUxQaVgzczZycGJhTWZTZVdrUldoQjN6VjBFdUhPeHg2cExra0ZsQUtxT29PNWM4bURuQ3Y1R1haRVcyLUJBRXdudm12YzhWczVWM2NFTWtaSHc2d012Nk1aRldpRmtCT3V3bGRfWEp2X0wxVlhiQmk0?oc=5","date":"2026-01-17","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money? - AD HOC NEWS","headline":"The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWXEyU0RyUGZXcUREckw0WnBubDFZMHlscFdOUUdPOW1DZHhWdFNQc2NNREZWN3liRkNvandYNGJpdUc5Q2hFWHk1enZBb1FvR09Wak41RUFIbXpPTTRhTFl6NlhBeHZ4b25TeVFKM0oxT3VJUlpQTzBDSHVHcm14NGNVQ0VwWUthb3BmMkUyWFRfYzBWc1pFdVdMRGVMOW1BWjJrdkNaX19udw?oc=5","date":"2026-01-15","type":"pipeline","source":"Seeking Alpha","summary":"Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha","headline":"Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNYTN0QnExWXZOZG9vUWdvS3dwWjJrcG5yTVZ0TDdOS3ZnNHUzSkhLWmVObmtmbzRYMGFRQS1odmt6Vkt2SWNKMHo0MFRTQjl2NFYxTmoyMlNmVEVKNi1jUEFTa182NXNGd3E5RDhsSV9CS0d5NmlLV2xnNUw4cXVyTENB?oc=5","date":"2026-01-10","type":"pipeline","source":"Yahoo Finance","summary":"Here’s What Analysts Think About Biogen Inc. (BIIB) - Yahoo Finance","headline":"Here’s What Analysts Think About Biogen Inc. (BIIB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQcV9Cc25CVllXcEJYX09sdVB1OGpYNnU0SGh0dm1MQTU3NXlJUmZUMDB0LURTYzBLT1lROXYxMkdJbTRheUhXNjFuSS1QMjVLTlpjRHdWbFR4a21jYlN0bGdKN3Y5Zk1GdmRiUDhpTkxPeUk4aHpQSVBRWElCWGJua09kSUpfdw?oc=5","date":"2025-12-10","type":"pipeline","source":"Seeking Alpha","summary":"AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha","headline":"AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5FQy1kWXI3bTdZM1NBTGRxaVB3RUp5dG4yUnRYTk9jVGF2cjFGY0h6QkhHNXYzTzctREY0cUVqLWw5enpCYUhWMUFYdXlOVWRZS1hzcUpIbVlHNWtURmY5eTRSMkhfMENnNG4zZEd3LXJkVlV6U0sya3FRTQ?oc=5","date":"2025-05-13","type":"pipeline","source":"Yahoo Finance","summary":"Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom - Yahoo Finance","headline":"Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPLW5Vbmd0c1FZbTd4MzduTnlKa19DS0tNRzlBRjlxMGhqdlhkNm5XUGFTcExGS2JDcHQyTmtQNk5OOGFIYkF5RFFwbXNOSWhRNmh2eW44TzhBNXdRZlVLOUZrb2p6c0VDQ2hqQzZvbUlQOFVCejRsNEd3MXpmQVlMcExFT3NtdnB1cFJjZDRBdTEwa2Y5c1ZLTURlczJFbVJaQVE?oc=5","date":"2023-07-28","type":"deal","source":"Biogen","summary":"Biogen to Acquire Reata Pharmaceuticals - Biogen","headline":"Biogen to Acquire Reata Pharmaceuticals","sentiment":"neutral"}],"patents":[{"drugName":"Tysabri","drugSlug":"natalizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Aduhelm","drugSlug":"aducanumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":61,"phaseCounts":{"marketed":24,"phase_3":13,"phase_2":14,"phase_1":10},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Roche Holding AG","Eli Lilly and Company","Novartis AG"],"therapeuticFocus":["Neurology","Autoimmune Disorders"],"financials":{"source":"sec_edgar","revenue":9890600000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":9890600000,"period":"2025-12-31"},{"value":9675900000,"period":"2024-12-31"},{"value":9835600000,"period":"2023-12-31"},{"value":10173400000,"period":"2022-12-31"},{"value":10981700000,"period":"2021-12-31"},{"value":13444600000,"period":"2020-12-31"}],"grossProfit":11639400000,"grossProfitHistory":[],"rdSpend":1334919000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":1292900000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":2913700000,"cashHistory":[],"totalAssets":29439500000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":177.09,"previousClose":175.61,"fiftyTwoWeekHigh":202.41,"fiftyTwoWeekLow":110.04,"fiftyTwoWeekRange":"110.04 - 202.41","fiftyDayAverage":186,"twoHundredDayAverage":159.45,"beta":0.16,"enterpriseValue":28614164480,"forwardPE":11.1,"priceToBook":1.42,"priceToSales":2.63,"enterpriseToRevenue":2.89,"enterpriseToEbitda":7.94,"pegRatio":3.68,"ebitda":3603699968,"ebitdaMargin":36.4,"freeCashflow":1981887488,"operatingCashflow":2204600064,"totalDebt":6657600000,"debtToEquity":36.5,"currentRatio":2.68,"returnOnAssets":6.1,"returnOnEquity":7.4,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":30,"targetMeanPrice":206.67,"targetHighPrice":275,"targetLowPrice":150,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.2,"institutionHeldPercent":98.3,"sharesOutstanding":146758528,"floatShares":146278628,"sharesShort":4334795,"shortRatio":4.83,"shortPercentOfFloat":2.9,"epsTrailing":8.8,"epsForward":16,"revenuePerShare":67.51,"bookValue":124.36,"officers":[{"age":64,"name":"Mr. Christopher A. Viehbacher","title":"President, CEO & Director"},{"age":52,"name":"Ms. Nicole  Murphy","title":"Executive VP and Head of Pharmaceutical Operations & Technology"},{"age":68,"name":"Ms. Susan H. Alexander Esq.","title":"Executive VP & Chief Legal Officer"},{"age":56,"name":"Dr. Priya  Singhal M.D., M.P.H.","title":"Executive VP & Head of Development"},{"age":59,"name":"Ms. Robin C. Kramer","title":"Executive VP & CFO"},{"age":51,"name":"Mr. Sean  Godbout","title":"VP, Chief Accounting Officer & Global Corporate Controller"},{"age":null,"name":"Mr. Guy  Hadari","title":"Chief Information Officer"},{"age":null,"name":"Mr. Tim  Power M.B.A., Ph.D.","title":"Head of Investor Relations"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.biogenidec.com/INVESTORS.aspx?ID=5494","website":"https://www.biogen.com","phone":"617 679 2000"}}